### SYMPOSIUM ON MUSCLE-BONE INTERACTION IN DUCHENNE MUSCULAR DYSTROPHY

**21ST JUNE 2019**  
St Virgil Conference Centre, Salzburg, Austria

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 0900-0910 | Welcome & introduction (10 min)  
*Dr. Jarod Wong, UK* |
| **MANAGEMENT OF DMD & APPROACH OF INVESTIGATIVE THERAPEUTIC TARGETS** | |
| 0910-0925 | DMD: A multi-system condition and importance of standards of care for clinical management (15 min talk)  
*Prof. Günther Bernert, Austria.* |
| 0925-0950 | Glucocorticoid treatment in DMD: Paediatric perspective (20 min talk, 5 min question)  
*Prof. Nathalie Goemans, Belgium* |
| 0950-1015 | Glucocorticoid treatment in DMD: Adult perspective (20 min talk, 5 min question)  
*Dr. Ros Quinlivan, UK* |
| 1015-1040 | Therapeutic targets in DMD & overview of DMD treatment clinical trials (20 min talk, 5 min question)  
*Dr. Michela Guglieri, UK* |
| 1040-1110 | Coffee (30 min) |
| **MUSCLE-BONE-GLUCOCORTICOID INTERACTION IN DMD** | |
| 1110-1140 | The muscle-bone cross talk and implications for neuromuscular conditions (25 min talk, 5 min question)  
*Prof. Frank Rauch, Canada* |
| 1140-1210 | Experimental models to study the effects of glucocorticoid on bone strength and growth (25min talk, 5 min question)  
*Prof. Colin Farquharson, UK* |
| 1210-1240 | Mechanism of glucocorticoid induced osteoporosis and lessons from adult trials (25 min talk, 5 min question)  
*Prof. Mark Cooper, Australia* |
| 1240-1325 | Lunch (45min) |
| **CLINICAL MANAGEMENT OF OSTEOPOROSIS IN DMD: STANDARDS OF CARE** | |
| 1325-1355 | Osteoporosis management in DMD and updated standards of care 2018 (25 min talk, 5 min question)  
*Dr. Jarod Wong, UK* |
| 1355-1420 | Identifying vertebral fractures and assessing fracture risk in DMD-Implementing the 2018 standards of care and developing research (20 min talk, 5 min question)  
*Dr. Nicola Crabtree, UK* |
| 1420-1445 | Puberty and growth management to improve bone health in DMD and updated standards of care 2018 (20 min talk, 5 min question)  
*Prof. Margaret Zacharin, Australia* |
| 1445 – 1500 | Discussion on Implementing Standards of Care (15 min) |
NEW THERAPEUTIC OPPORTUNITIES TO IMPROVE MUSCLE-BONE IN DMD

1500-1525 Vibration therapy to improve muscle-bone in neuromuscular conditions (20 min talk, 5 min question)
   Dr. Ibrahim Duran, Germany

1525-1545 Dissociative steroids in DMD: Impact on bone and endocrine axis (20 min talk, 5 min question)
   Prof. Eric Hoffman, USA

1545-1610 Targeting Nuclear Factor Kappa-B with Edasalonexent for Muscle and Bone Health in DMD (20 min talk, 5 min question)
   Dr Joanne Donovan, USA

1610-1635 RANKL inhibition to target muscle and bone in DMD (20 min talk, 5 min question)
   Prof. Jerome Frenette, Canada

1635-1655 Coffee (20 min)

DEVELOPING OSTEOPOROSIS CLINICAL TRIALS IN DMD AND FUTURE DIRECTIONS

1655-1735 A critical appraisal of anti-resorptive and anabolic therapies to improve bone health in DMD (35 min talk, 5 min question)
   Prof. Leanne Ward, Canada

1735-1800 Patient perspective of osteoporosis clinical trials (20 min talk, 5 min question)
   Ms. Elizabeth Vroom, Netherlands (Duchenne Parent Project) / Ms. Pat Furlong, USA (Parent Project Muscular Dystrophy)

1800-1820 Update from European Neuromuscular Centre workshop on developing osteoporosis trials in DMD (15 min talk, 5 min question)
   Dr. Jarod Wong, UK

1820-1900 Discussion (40 min)
   With focus on data sharing and the path forward
   Dr. Michela Guglieri & Dr. Jarod Wong